141 related articles for article (PubMed ID: 27569750)
1. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Vultaggio A; Petroni G; Pratesi S; Nencini F; Cammelli D; Milla M; Prignano F; Annese V; Romagnani S; Maggi E; Matucci A;
Clin Exp Immunol; 2016 Dec; 186(3):364-372. PubMed ID: 27569750
[TBL] [Abstract][Full Text] [Related]
2. T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.
Pratesi S; Nencini F; Grosso F; Dies L; Bormioli S; Cammelli D; Maggi E; Matucci A; Vultaggio A;
Front Immunol; 2018; 9():3113. PubMed ID: 30687319
[TBL] [Abstract][Full Text] [Related]
3. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
Nencini F; Vultaggio A; Pratesi S; Cammelli D; Milla M; Fiori G; Bagnoli S; Prignano F; Romagnani S; Maggi E; Matucci A
J Allergy Clin Immunol Pract; 2018; 6(6):2065-2072.e2. PubMed ID: 29660428
[TBL] [Abstract][Full Text] [Related]
4. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution.
Vultaggio A; Nencini F; Carraresi A; Pratesi S; Movérare R; Eriksson C; Venemalm L; Maggi E; Matucci A
Allergy; 2018 Nov; 73(11):2172-2181. PubMed ID: 29719053
[TBL] [Abstract][Full Text] [Related]
5. IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients.
Vultaggio A; Nencini F; Pratesi S; Cammelli D; Totaro M; Romagnani S; Maggi E; Matucci A;
J Immunol; 2017 Aug; 199(4):1283-1289. PubMed ID: 28716826
[TBL] [Abstract][Full Text] [Related]
6. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
7. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab.
Matucci A; Pratesi S; Petroni G; Nencini F; Virgili G; Milla M; Maggi E; Vultaggio A
Clin Exp Allergy; 2013 Jun; 43(6):659-64. PubMed ID: 23711128
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
[TBL] [Abstract][Full Text] [Related]
9. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
10. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.
van Schie KA; Ooijevaar-De Heer P; Kruithof S; Plasencia C; Jurado T; Pascual Salcedo D; Brandse JF; d'Haens GR; Wolbink GJ; Rispens T
Ann Rheum Dis; 2017 Jul; 76(7):1285-1288. PubMed ID: 28455438
[TBL] [Abstract][Full Text] [Related]
11. Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis.
Takeshita M; Suzuki K; Kikuchi J; Izumi K; Kurasawa T; Yoshimoto K; Amano K; Takeuchi T
Cytokine; 2015 Oct; 75(2):222-7. PubMed ID: 26095743
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.
Kattah MG; Milush JM; Burt T; McCabe RP; Whang MI; Ma A; Mahadevan U
Clin Transl Gastroenterol; 2018 Apr; 9(4):143. PubMed ID: 29618720
[TBL] [Abstract][Full Text] [Related]
13. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay.
Van Stappen T; Brouwers E; Vermeire S; Gils A
Drug Test Anal; 2017 Feb; 9(2):243-247. PubMed ID: 26990872
[TBL] [Abstract][Full Text] [Related]
14. Changes in the pattern of cytokine production from peripheral blood mononuclear cells in patients with rheumatoid arthritis treated with infliximab and their relation to plasma arginase activity.
Miyoshi F; Sato K; Mimura T
Int J Rheum Dis; 2018 Nov; 21(11):1907-1914. PubMed ID: 30592386
[TBL] [Abstract][Full Text] [Related]
15. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
Vultaggio A; Matucci A; Nencini F; Pratesi S; Parronchi P; Rossi O; Romagnani S; Maggi E
Allergy; 2010 May; 65(5):657-61. PubMed ID: 19951375
[TBL] [Abstract][Full Text] [Related]
17. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
[TBL] [Abstract][Full Text] [Related]
18. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease.
Agnholt J; Kaltoft K
Cytokine; 2001 Aug; 15(4):212-22. PubMed ID: 11563881
[TBL] [Abstract][Full Text] [Related]
19. β-Lactam hypersensitivity involves expansion of circulating and skin-resident T
Sullivan A; Wang E; Farrell J; Whitaker P; Faulkner L; Peckham D; Park BK; Naisbitt DJ
J Allergy Clin Immunol; 2018 Jan; 141(1):235-249.e8. PubMed ID: 28219704
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
